A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Recruiting now · Phase 1/Phase 2

Conditions studied: Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging

In brief

A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS

Key facts

Study ID

NCT06906471

Run by

Antelope Surgical Solutions, Inc

People needed

10

Starts

2026-07-01

Expected to finish

2026-12-30

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• suspected prostate cancer warranting standard of care multi-core prostate biopsy

You may not qualify if…

• Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
• Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature
• Patients with a creatinine clearance cutoff (CrCl) of < 60 mL/min

Where it is running

• HCA Florida Kendall Hospital — Miami, Florida, United States (enrolling)
• Icahn School of Medicine at Mount Sinai (ISMMS) — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.